Helix Biopharma Corp. (TSE:HBP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced the ongoing delay in filing its interim financial statements, indicating that they are working diligently to complete the filings as soon as possible. The Ontario Securities Commission has issued a management cease trade order that restricts company executives from trading shares, although it does not affect shareholder trading. Meanwhile, Helix successfully closed a private placement offering, raising CAD$1.915 million without reporting any additional material changes or anticipated defaults.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.